Overall survival of 182 patients with high-grade malignant B-cell lymphomas treated by the COP-BLAM/IMVP-16 regimen (BMFT trial5 ); (patients at risk at 1/2/3/4 years). Lymphoma subtypes (Kiel classification): ———, centroblastic n = 127 (87/69/52/19); - - - -, B-anaplastic large cell (CD30⁺) n = 22 (13/8/4/1); ⋅⋅⋅⋅, B-immunoblastic n = 33 (20/8/5/4) P = .0005.